Regeneron Inc. has filed a motion seeking the disqualification of the prestigious law firm Kirkland & Ellis from representing Novartis AG in an ongoing antitrust and patent litigation. The motion arises out of concerns that Kirkland & Ellis, having previously worked for Regeneron, has switched allegiances in a manner that presents a conflict of interest. Bloomberg Law reports that Regeneron had engaged Kirkland between 2020 and 2022 to aid in the development of a global intellectual property strategy for EYLEA, a medication aimed at treating eye diseases.
The controversy centers around Kirkland & Ellis now representing Novartis, which is alleged to have conspired to prevent the introduction of EYLEA in the United States, a claim that forms a critical aspect of the litigation. Regeneron’s legal counsel, Kimo Peluso, emphasized that it is unexpected for Kirkland to litigate against Regeneron in a case where it previously held a consulting role.
This case continues to unfold, and observers in the legal community are keenly watching the implications it may have on the professional conduct rules related to conflicts of interest. The motion raises significant questions about the duties and ethical obligations of law firms when shifting representation between competing clients.